Fintech PR
Fitwel Announces Certified Metrics Pilot to Substantiate Value & Risk
In Collaboration with EVORA Global, New Pilot Marks Codification of Metrics Connecting Health and Well-Being to “S” in ESG for Commercial Real Estate Industry
NEW YORK, Sept. 13, 2023 /PRNewswire/ — Fitwel®, the healthy building certification platform operated by the Center for Active Design (CfAD) and Active Design Advisors Inc. (Adai), announced today the launch of its Certified Metrics pilot in partnership with sustainable technology and services company EVORA Global. A global first for the industry, the new tool is a giant step forward in validating data for real estate, addressing the growing need for a rigorous and standardized approach to integrate the ‘Social,” including health and well-being measures, into ESG reporting.
Voluntary ESG reporting is booming, but 46% of investors find the ‘S’ to be the most difficult ESG factor to analyze and embed into investment strategies (BNP Paribas, 2019). 69% of investors believe having an external certification or validation would give them more confidence in assessing the accuracy of a company’s reporting (PwC, 2022), and so the Certified Metrics is a direct response to industry demand.
Certified Metrics will enable real estate firms to assess an entire fund or portfolio against an evidence-based standard, generate data insights about social and material risk, verify their performance through a third-party review, and compare that performance to peers. Certified Metrics can be used across funds and portfolios with a variety of asset types, ultimately delivering data-driven insights to inform investment decisions. Fitwel’s entity-level solution builds on the latest health evidence base by, for the first time, connecting health outcomes with economic value, pointing to clear substantiation of value and risk.
Certified Metrics offers an answer to a question the global market has asked for some time: how do we quantify and validate the “Social” component of ESG for real estate investors, and how can it be applied universally? Europe has largely been at the forefront of developing solutions to this question, and now, EVORA and Fitwel will standardize a solution that can be successful globally. The key to this anticipated success is in providing an evidence-based reporting framework that will result in verified outcomes, thus making Social reporting clear and straightforward industry-wide.
The pilot is part of Fitwel’s ever-growing suite of product offerings as it expands beyond its flagship role as a healthy building certification to a comprehensive data and insights platform that drives market transformation for the industry. Earlier this year, Fitwel released its Relational Data Insights Tool which measures asset performance of Fitwel-certified projects.
“Given that ‘S’ metrics are still in their infancy in terms of ESG reporting, what matters most is where you stand in relation to the rest of the market,” according to Joanna Frank, Fitwel President & CEO. “This is the appeal of Certified Metrics – in offering a much-needed pathway for companies to maximize the value they are creating by prioritizing health.”
“For the first time, we will have a codified standard for social impact in real estate across the world,” said Sarah Coughlan, EVORA Global Associate Director. “Codification is a major milestone for ‘Social’ as it has long suffered from a lack of comparable metrics and benchmarks. This is no longer the case. Acting as industry partners, EVORA has been working with Fitwel to develop a widely applicable standard that works across all asset classes. The Social pillar is finally maturing and I’m very proud that EVORA is helping to drive this change.”
The first phase of the Certified Metrics pilot will be led by Fitwel Leadership Advisory Board (LAB) members BGO, Hudson Pacific Properties, Lendlease Americas, QuadReal Property Group, Tishman Speyer, and Vornado Realty Trust. The full pilot cohort, which will soon be announced, is expected to focus on six targeted outcomes with proven impact on health and financial value: Supporting a High-Quality Environment; Creating Climate Change Resilience & Preparedness; Engaging with Occupants and Community Stakeholders; Promoting Equity; Optimizing Asset for Walking & Active Transportation; and Enhancing Access to Natural Elements.
Fitwel Certified Metrics will deliver increased value by providing:
- A report showcasing a fund or portfolio’s certified metrics, including key stats and narratives to bolster regulation and compliance reporting as well as marketing and ESG submissions
- Rankings to provide valuable insights on how a fund performs compared to others in the industry
- A gap analysis highlighting specific areas for targeted investment and improvement over time
“EVORA’s long-standing relationship with Fitwel has moved a step closer now thanks to our collaboration on the Certified Metrics standard,” shared Philippa Gill, EVORA Global Executive Director, Strategic Accounts. “We are delighted to be part of the first independent industry framework to address social wellbeing and climate resilience factors and look forward to further insights from our pilot scheme participants who are key to ensuring the metrics can be adopted across global markets.”
About Fitwel
Fitwel is the world’s leading certification system committed to building health for all. Generated by expert analysis of 7,000+ academic research studies, Fitwel is implementing a vision for a healthier future where all buildings and communities are enhanced to strengthen health and well-being. Fitwel was originally created by the U.S. Centers for Disease Control (CDC) and Prevention and U.S. General Services Administration. The CDC remains the research and evaluation partner for Fitwel. The Center for Active Design (CfAD), a global not-for-profit organization, maintains the Fitwel standard and conducts objective third-party assessments that lead to certified projects. CfAD’s new business unit, Adai (pronounced “a-DAY”), is charged with expanding Fitwel to the global market, administering the program while providing best-in-class customer service and technical support. To learn more about Fitwel, please visit: www.fitwel.org.
About Evora Global
EVORA Global is a premier sustainability advisor, providing comprehensive, industry-leading climate solutions for real asset investors. EVORA works with clients to improve their sustainability and reduce their climate risk. Its clients include many of the biggest names in global real estate, including Invesco Real Estate, Hines and M&G. The company provides consultancy services and has developed its own software, SIERA, which enables its clients to make investment decisions regarding climate change and sustainability. Founded in 2011 by Chris Bennett, Ed Gabbitas and Paul Sutcliffe, the company now has over 200 staff.
View original content:https://www.prnewswire.co.uk/news-releases/fitwel-announces-certified-metrics-pilot-to-substantiate-value–risk-301925688.html
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News4 days ago
Letter from Gatemore Capital Management LLP to Elementis PLC
-
Latest News4 days ago
Shanghai Electric Releases ESG Report, Highlighting Sustainable Development Achievements in 2023
-
Latest News4 days ago
Hyosung Heavy Industries Ranked on BNEF’s Energy Storage Tier 1 List
-
Latest News4 days ago
Talino, Chemonics invest in startup Higala, the Philippines’ pioneering inclusive instant payment system
-
Latest News7 days ago
Former Tesla executive Tim Newell is set to spin off Aspiration’s consumer financial services division.
-
Latest News7 days ago
United Imaging Healthcare releases 2023 annual report, with revenue growth of 23.52%
-
Latest News7 days ago
Indian fintech firm Aurionpro has expanded its artificial intelligence (AI) capabilities with the acquisition of Arya.ai for $16.5 million.
-
Latest News7 days ago
Morgan Stanley B.V. – annual report and financial statements for the financial year ended 31 December 2023